SCHEMBL3480796

SCHEMBL3480796

Nc1nc2cc(OCCCCl)c(OCCCCl)cc2s1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.46
TP53 P04637 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
ALDH1A1 P00352 2/20 0.46
TSHR P16473 2/20 0.46
HSD17B10 Q99714 2/20 0.44
PIK3CD O00329 5/20 0.43
PI4KA P42356 5/20 0.43
PIK3CG P48736 5/20 0.43
PI4KB Q9UBF8 5/20 0.43
PIK3CA P42336 4/20 0.43
PIK3CB P42338 4/20 0.43
RAB9A P51151 4/20 0.41
NPC1 O15118 3/20 0.41
CYP1A2 P05177 2/20 0.41
GAA P10253 2/20 0.41
GMNN O75496 1/20 0.41
USP2 O75604 1/20 0.41
LMNA P02545 1/20 0.41
ADORA3 P0DMS8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3480328 0.94 CYP3A4 (0.46) CYP3A4TP53SMN1; SMN2ALDH1A1TSHR
SCHEMBL3480200 0.81 STING1 (0.31) RAB9ANPC1GAAPDE4DMAPK1
SCHEMBL11674379 0.80 CYP3A4 (0.62) CYP3A4TP53SMN1; SMN2ALDH1A1TSHR
SCHEMBL9722731 0.75 CYP3A4 (0.56) CYP3A4TP53SMN1; SMN2ALDH1A1TSHR
SCHEMBL3480101 0.74 STING1 (0.31) RAB9ANPC1GAAMAPK1
SCHEMBL9297465 0.74 SMN1; SMN2 (0.52) TP53SMN1; SMN2ALDH1A1HSD17B10RAB9A
SCHEMBL31114638 0.74 CYP3A4 (0.59) CYP3A4TP53SMN1; SMN2ALDH1A1TSHR
SCHEMBL9722790 0.74 CYP3A4 (0.59) CYP3A4TP53SMN1; SMN2ALDH1A1TSHR
SCHEMBL21667829 0.74 EHMT2 (0.64) DRD2
SCHEMBL29752153 0.74 CYP3A4 (0.68) CYP3A4TP53SMN1; SMN2ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2049200-B1 NOVEL INHIBITORS OF BETA-LACTAMASE METHYLGENE INC (CA) 2015-04-29 EP disclosed
US-8440643-B2 Inhibitors of beta-lactamase METHYLGENE INC. (CA) 2013-05-14 US disclosed
US-20100317625-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE 92229129 QUEBEC INC. (CA) 2010-12-16 US disclosed
US-20100279983-A1 NOVEL INHIBITORS OF BETA-LACTAMASE METHYLGENE INC. 2010-11-04 US disclosed
EP-2049200-A2 NOVEL INHIBITORS OF BETA-LACTAMASE MethylGene Inc. (CA) 2009-04-22 EP disclosed
EP-2024376-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE Merck & Co., Inc. (US) 2009-02-18 EP disclosed
WO-2008073142-A2 NOVEL INHIBITORS OF BETA-LACTAMASE MERCK & CO., INC. (US) 2008-06-19 WO disclosed
WO-2007139729-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE MERCK & CO., INC. (US) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317625-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE MGAM, BPGM, PPME1 CYP3A4 1244/4885TP53 4460/4885SMN1; SMN2 3461/4885
US-20100279983-A1 NOVEL INHIBITORS OF BETA-LACTAMASE MGAM, MGAM2, PGLS CYP3A4 1281/4885TP53 4583/4885SMN1; SMN2 3467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.